[go: up one dir, main page]

WO1996006846A1 - Nouveaux derives d'aryle piperazines - Google Patents

Nouveaux derives d'aryle piperazines Download PDF

Info

Publication number
WO1996006846A1
WO1996006846A1 PCT/ES1995/000094 ES9500094W WO9606846A1 WO 1996006846 A1 WO1996006846 A1 WO 1996006846A1 ES 9500094 W ES9500094 W ES 9500094W WO 9606846 A1 WO9606846 A1 WO 9606846A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyano
trifluoromethyl
amino
bromo
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES1995/000094
Other languages
English (en)
Spanish (es)
Inventor
Maria Luz Lopez Rodriguez
Maria Luisa Rosado Samitier
Bellinda Benahmu Salama
Esther Fernandez Velando
Maria Jose Morcillo Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES9401895A external-priority patent/ES2082727B1/es
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to AU30792/95A priority Critical patent/AU3079295A/en
Priority claimed from ES9501534A external-priority patent/ES2095811B1/es
Publication of WO1996006846A1 publication Critical patent/WO1996006846A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention concerns new compounds of general formula JL where X is - (CH 2 ) 3 - or - (CH 2 ) 4 -; m is equal to 0 or 1; n is equal to 1, 2, 3 or 4; Ar is 1-naphthyl, 7-benzofuranyl, 2,3-dihydro-l, 4-benzodioxan-5-yl, 3,4-dihydro-2i-l, 5-benzodioxepin-6-yl, phenyl or alkyl substituted phenyl , halogen, trifluoromethyl, nitro, cyano, alkoxy, amino, alkylcarbamoyl, alkylsulfonamido or alkoxycarbonyl.
  • 5-HT 1A receptor agonists play in controlling anxiety and depression (M. Hamon, Trends Pharmacol. Sci. 1994, 15, 36; P. Blier and C. Montigny, Trends Pharmacol. Sci. 1994, 15, 220). So far, the only 5-HT agonist, A marketed is buspirone. However, this drug lacks specificity on said receptor, since it is capable of binding to other types of receptors (dopaminergic, ⁇ -yo adrenergic, ⁇ -aminobutyric acid (GABA) -benzodiazepines and muscarinic).
  • GABA ⁇ -aminobutyric acid
  • the present invention relates to new arylpiperazine derivatives, which have shown a high affinity for the 5-HT, A receptor.
  • the new arylpiperazine derivatives are represented by the general formula I:
  • X is - (CH 2 ) 3 - or - (CH 2 ) 4 -; m is equal to 0 or 1; n is equal to 1, 2, 3 or 4
  • R 1 , R 2 and R 3 is hydrogen, alkyl, halogen tri-fluoromethyl, nitro, cyano, alkoxy, amino, alkylcarbamoyl, alkylsulfonamido or alkoxycarbonyl
  • Non-commercial 1-arylpiperazines have been obtained according to the methods described in the literature: J. A. Chem. Soc, 76, 1853 (1954); J. Med. Chem., 32, 1052 (1989); JP61, 152,655; J. Med. Chem., 31, 1934 (1988).
  • the starting products of formula m are obtained by treating the L-proline or ethyl pipecolinate with 2-chloroethyl isocyanate.
  • affinities of some of the compounds of general structure I by the serotonergic 5-HT 1A receptor in rat cerebral cortex membranes were determined by radioligand techniques using 3 H-8-OH-DPAT [8-hydroxy-2- (di -n-propylamino) tetralin] with selective ligand.
  • mice Male albino rats (Rattus norvegicus albimts), Sprague-Dawley breed, weighing approximately 200 g, are sacrificed by decapitation. Brains are quickly removed and frozen in liquid nitrogen. The tissue is stored at -40 ° C until it is used.
  • the cerebral cortex is homogenized in 10 volumes of 50 mM Tris-HCl buffer, pH 7, at 25 ° C and centrifuged at 28000 x g for 15 min, at 4 ° C. The supernatant is neglected and sediment is washed twice by resuspension and centrifugation under the conditions described.
  • the resuspended sediment is incubated at 37 ° C for 10 min.
  • the membranes are centrifuged again and the pellet is resuspended in 10 volumes of Tris-HCl buffer with 5 mM MgSO 4 and 0.5 mM NajEDTA (pH 7.4 at 25 ° C).
  • Fractions of 100 ⁇ l of the final suspension of the membranes (5 mg / ml protein) are incubated for 10 min at 37 ° C with 3 H 8-OH-DPAT 0.6 nM in the presence or absence of the compound under study in an end volume of 1.1 ml of 50 mM Tris-HCl buffer, pH 7.4.
  • Non-specific binding is determined with 10 ⁇ M serotonin.
  • the bound radioactive ligands are separated from the free ones by vacuum filtration on Whatman GF / B filter washed twice with 4 ml of 50 M Tris-HCl buffer, pH 7.4 at 4 ° C. After sec the filters for one hour at 60 ° C, 4 ml of scintillation liquid (Aquasol) are added and the radioactivity bound to the membranes is measured by liquid scintillation spectrometry.
  • Whatman GF / B filter washed twice with 4 ml of 50 M Tris-HCl buffer, pH 7.4 at 4 ° C. After sec the filters for one hour at 60 ° C, 4 ml of scintillation liquid (Aquasol) are added and the radioactivity bound to the membranes is measured by liquid scintillation spectrometry.
  • Aquasol scintillation liquid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de formule générale (I), dans laquelle X représente -(CH2)3-O-(CH2)4-; m est égal à 0 ou 1; n est égal à 1, 2, 3 ou 4; Ar représente 1-naphthyle, 7-benzofuranyle, 2,3-dihidro-1,4-benzodioxane-5-yle, 3,4-dihydro-2H-1,5-benzodioxépine-6-yle, phényle ou phényle substitué par alkyle, halogène, trifluorométhyle, nitro, cyano, alcoxy, amino, alkylcarbamyle, alkylsulfonamido ou alcoxy carbonylo. L'invention concerne également les différents procédés de préparation de ces composés, lesquels présentent une affinité pour le récepteur sérotoninergique 5-HT1A, mettant en évidence son utilité du point de vue thérapeutique dans le traitement des troubles du SNC, tels que l'anxiété et la dépression.
PCT/ES1995/000094 1994-09-01 1995-07-28 Nouveaux derives d'aryle piperazines Ceased WO1996006846A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30792/95A AU3079295A (en) 1994-09-01 1995-07-28 New arylpiperazine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ESP9401895 1994-09-01
ES9401895A ES2082727B1 (es) 1994-09-01 1994-09-01 Nuevos derivados de arilpiperazinas.
ES9501534A ES2095811B1 (es) 1995-07-28 1995-07-28 Nuevos derivados de arilpiperazinas.
ESP9501534 1995-07-28

Publications (1)

Publication Number Publication Date
WO1996006846A1 true WO1996006846A1 (fr) 1996-03-07

Family

ID=26154819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES1995/000094 Ceased WO1996006846A1 (fr) 1994-09-01 1995-07-28 Nouveaux derives d'aryle piperazines

Country Status (2)

Country Link
AU (1) AU3079295A (fr)
WO (1) WO1996006846A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015527A1 (fr) * 1997-09-23 1999-04-01 Universidad Complutense De Madrid PROCEDE D'OBTENTION DU 2-[4-[4-(m- ETHYLSULFONAMIDOPHENYL) PIPERAZINE-1-YL] BUTYL]-1,3- DIOXOPERHYDROPYRROLO [1,2-c]IMIDAZOL
ES2154605A1 (es) * 1999-09-14 2001-04-01 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6974823B2 (en) 1999-12-21 2005-12-13 Gpi Nil Holdindgs, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
EP1674103A1 (fr) * 2004-12-27 2006-06-28 Cepa Schwarz Pharma s.l. Dérivés d'arylpiperazines et leurs utilisations en tant que ligands du récepteur 5-HT1A
US7078424B2 (en) 1998-06-03 2006-07-18 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
US7153883B2 (en) 1998-06-03 2006-12-26 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US7351732B2 (en) 2002-07-31 2008-04-01 Schwarz Pharma S.L. Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications
WO2023135528A1 (fr) 2022-01-11 2023-07-20 Suven Life Sciences Limited Dérivés hétéroalicycliques et leur utilisation dans le traitement de troubles du snc

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2092785A1 (en) * 1970-06-18 1972-01-28 Hokuriku Pharmaceutical 2-azaquinolizidine derivs and salts neurotropic and anti - -histamine agents synthesis
US3717634A (en) * 1969-11-24 1973-02-20 Mead Johnson & Co N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones
EP0256936A1 (fr) * 1986-08-12 1988-02-24 Rhone-Poulenc Sante Nouveaux dérivés de la benzyl-4 pipérazine, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0296048A1 (fr) * 1987-06-15 1988-12-21 Adir Et Compagnie Nouveaux dérivés de la pipérazinyl alkyl piperazine dione, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
EP0362555A1 (fr) * 1988-09-03 1990-04-11 Hoechst Aktiengesellschaft Pipérazinediones à activité psychotrope

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717634A (en) * 1969-11-24 1973-02-20 Mead Johnson & Co N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones
FR2092785A1 (en) * 1970-06-18 1972-01-28 Hokuriku Pharmaceutical 2-azaquinolizidine derivs and salts neurotropic and anti - -histamine agents synthesis
EP0256936A1 (fr) * 1986-08-12 1988-02-24 Rhone-Poulenc Sante Nouveaux dérivés de la benzyl-4 pipérazine, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0296048A1 (fr) * 1987-06-15 1988-12-21 Adir Et Compagnie Nouveaux dérivés de la pipérazinyl alkyl piperazine dione, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
EP0362555A1 (fr) * 1988-09-03 1990-04-11 Hoechst Aktiengesellschaft Pipérazinediones à activité psychotrope

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. PERRONE ET AL.: "Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphtalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 1, WASHINGTON US, pages 99 - 104 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129370A1 (es) * 1997-09-23 1999-06-01 Univ Madrid Complutense Procedimiento para la obtencion del 2-(4-(4-(m-etilsulfonamidofenil)p iperazin-1-il(butil)-1,3-dioxoperhidropirrolo)1,2-c(imidazol
WO1999015527A1 (fr) * 1997-09-23 1999-04-01 Universidad Complutense De Madrid PROCEDE D'OBTENTION DU 2-[4-[4-(m- ETHYLSULFONAMIDOPHENYL) PIPERAZINE-1-YL] BUTYL]-1,3- DIOXOPERHYDROPYRROLO [1,2-c]IMIDAZOL
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US7078424B2 (en) 1998-06-03 2006-07-18 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
US7459473B2 (en) 1998-06-03 2008-12-02 Glia Med, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
US7153883B2 (en) 1998-06-03 2006-12-26 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
ES2154605A1 (es) * 1999-09-14 2001-04-01 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6974823B2 (en) 1999-12-21 2005-12-13 Gpi Nil Holdindgs, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
US7351732B2 (en) 2002-07-31 2008-04-01 Schwarz Pharma S.L. Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications
WO2006069993A1 (fr) * 2004-12-27 2006-07-06 Schwarz Pharma S.L. Derives d’arylpiperazine et leur utilisation comme ligands du recepteur as 5-ht1a
EP1674103A1 (fr) * 2004-12-27 2006-06-28 Cepa Schwarz Pharma s.l. Dérivés d'arylpiperazines et leurs utilisations en tant que ligands du récepteur 5-HT1A
WO2023135528A1 (fr) 2022-01-11 2023-07-20 Suven Life Sciences Limited Dérivés hétéroalicycliques et leur utilisation dans le traitement de troubles du snc
US12391698B2 (en) 2022-01-11 2025-08-19 Suven Life Sciences Limited Substituted piperidines and piperazines and methods for the treatment of CNS disorders

Also Published As

Publication number Publication date
AU3079295A (en) 1996-03-22

Similar Documents

Publication Publication Date Title
ES2246399T3 (es) 1,2,3,4-tetrahidroisoquinolinas como antagonistas derivados del receptor de urotensina ii.
JP2721147B2 (ja) α１−アドレナリン受容体拮抗剤としてのピリミジンジオン、ピリミジントリオン、トリアジンジオン、テトラヒドロキナゾリンジオン誘導体
RU2028297C1 (ru) Производные пиримидин-4-она или их фармацевтически приемлемые соли и серотонинантагонистическая, допаминантагонистическая и антигистаминная композиция на их основе
US6787535B2 (en) Indole derivatives with 5HT6 receptor affinity
CA2012628C (fr) Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
Chern et al. Studies on quinazolines. 5. 2, 3-Dihydroimidazo [1, 2-c] quinazoline derivatives: a novel class of potent and selective. alpha. 1-adrenoceptor antagonists and antihypertensive agents
RU2118322C1 (ru) 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
CA2334970A1 (fr) Inhibiteurs quinazolinone de la phosphodiesterase cgmp
PL191489B1 (pl) Pochodna 2-arylo-8-oksodihydropuryny, sposób jej wytwarzania i jej zastosowanie, zawierająca ją kompozycja farmaceutyczna, zawierający ją środek do leczenia oraz zawierający ją środek przeciwlękowy
AU2002310747A1 (en) New indole derivatives with 5-HT6 receptor affinity
JP2004505975A (ja) ベンズイミダゾール誘導体、その製造及び治療上の使用
HU198931B (en) Process for producing 2-square brackets open /piperidin-4-yl/-methyl square brackets closed -1,2,3,4-tetradihydro-9h-pyrido/3,4-b/indole derivatives and pharma ceutical compositions comprising same
AU721102B2 (en) 1H-pyrido{3,4-b}indole-4-carboxamide derivatives, their preparation and their application in therapeutics
AU4376897A (en) Novel indole-2,3-dione-3-oxime derivatives
WO1996006846A1 (fr) Nouveaux derives d'aryle piperazines
AU675880B2 (en) 1(2H-1-benzopyran-2-one-8-yl)-piperazine derivatives
US6821984B2 (en) Ring fused pyrazole derivatives as CRF antagonists
US7491729B2 (en) 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof
US5919788A (en) 4-(1H-indol-1-yl)-1-piperidinyl derivatives
CZ290011B6 (cs) Deriváty 4-oxo-3,5­dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostředek, který je obsahuje
FI92203B (fi) Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
US5512590A (en) 5,6-dihydro-4h-imidazo 2',1':2,3!imidazo- 4,5,1-ij!quinoline and 4,5-dihydroimidazo- 1,2-a!pyrolo 1,2,3-cd!benzimidazole derivatives, their preparation and application in therapeutics
NO172437B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidindionforbindelser
AU679938B2 (en) 3-oxo-pyrido(1-2-A)benzimidazole-4-carboxyl and 4-oxo-azepino(1-2-A)benzimidazole-5-carboxyl derivatives in treating central nervous system disorders
US5466706A (en) 9H-imidazo[1,2-A]benzimidazole-3-acetamide derivatives, their preparation and their therapeutic application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA